{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:51:08Z","timestamp":1790736668622,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012051","name":"Lupus Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jaut.2022.102858","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T03:57:24Z","timestamp":1657252644000},"page":"102858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["GILZ regulates type I interferon release and sequesters STAT1"],"prefix":"10.1016","volume":"131","author":[{"given":"Champa","family":"Nataraja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Dankers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Northcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Sherlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylah J.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan E.","family":"Russ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehnaz","family":"Pervin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"D'Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F.","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9571-3289","authenticated-orcid":false,"given":"Sarah A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaut.2022.102858_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaut.2022.102858_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.rdc.2021.04.012","article-title":"Treatment update in systemic lupus erythematous","volume":"47","author":"Hoi","year":"2021","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.jaut.2022.102858_bib3","first-page":"i114","article-title":"It hasn't gone away: the problem of glucocorticoid use in lupus remains","volume":"56","author":"Apostolopoulos","year":"2017","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.jaut.2022.102858_bib4","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(19)30105-5","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study","volume":"2","author":"Apostolopoulos","year":"2020","journal-title":"The Lancet Rheumatology"},{"issue":"8","key":"10.1016\/j.jaut.2022.102858_bib5","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/rheumatology\/keu148","article-title":"Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus","volume":"53","author":"Ruiz-Arruza","year":"2014","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.jaut.2022.102858_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1074-7613(00)00053-4","article-title":"Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha\/beta gene induction","volume":"13","author":"Sato","year":"2000","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.jaut.2022.102858_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ni1118","article-title":"Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6","volume":"5","author":"Kawai","year":"2004","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2022.102858_bib8","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.4049\/jimmunol.173.3.1535","article-title":"Regulation of IFN regulatory factor-7 and IFN-alpha production by enveloped virus and lipopolysaccharide in human plasmacytoid dendritic cells","volume":"173","author":"Dai","year":"2004","journal-title":"J. Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2022.102858_bib9","first-page":"A42","article-title":"Depletion of plasmacytoid dendritic cells with JNJ-56022473 minimises induction of an interferon gene signature in response to TLR9 and SLE immune complex stimulation","volume":"4","author":"Monaghan","year":"2017","journal-title":"Lupus Science & Medicine"},{"issue":"3","key":"10.1016\/j.jaut.2022.102858_bib10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.38966","article-title":"Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-alpha production","volume":"67","author":"Zhan","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.jaut.2022.102858_bib11","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.cell.2016.05.057","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jaut.2022.102858_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.immuni.2008.05.012","article-title":"A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus","volume":"29","author":"Chaussabel","year":"2008","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.jaut.2022.102858_bib13","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with SLE reveal distinct type I and type II interferon signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.jaut.2022.102858_bib14","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/0961203309105529","article-title":"Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus","volume":"18","author":"Petri","year":"2009","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.jaut.2022.102858_bib15","doi-asserted-by":"crossref","first-page":"E357","DOI":"10.1016\/S2665-9913(21)00006-0","article-title":"Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study","volume":"3","author":"Northcott","year":"2021","journal-title":"Lancet Rheumatology"},{"issue":"7300","key":"10.1016\/j.jaut.2022.102858_bib16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nature09102","article-title":"TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus","volume":"465","author":"Guiducci","year":"2010","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jaut.2022.102858_bib17","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/art.27566","article-title":"Glucocorticoid-induced leucine zipper is an endogenous antiinflammatory mediator in arthritis","volume":"62","author":"Beaulieu","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2022.102858_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.652800","article-title":"GILZ regulates the expression of pro-inflammatory cytokines and protects against end-organ damage in a model of lupus","volume":"12","author":"Nataraja","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2022.102858_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/annrheumdis-2015-207744","article-title":"Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus","volume":"75","author":"Jones","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.jaut.2022.102858_bib20","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s10067-017-3711-9","article-title":"Glucocorticoid-induced leucine zipper expression is associated with response to treatment and immunoregulation in systemic lupus erythematosus","volume":"36","author":"Mohammadi","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102858_bib21","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M111.279257","article-title":"Novel p65 binding GILZ peptide suppresses experimental autoimmune encephalomyelitis","author":"Srinivasan","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jaut.2022.102858_bib22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4049\/jimmunol.1202662","article-title":"GILZ overexpression inhibits endothelial cell adhesive function through regulation of NF-kappaB and MAPK activity","volume":"191","author":"Cheng","year":"2013","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2022.102858_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/nar\/gkl1080","article-title":"Glucocorticoid-induced leucine zipper (GILZ)\/NF-kappaB interaction: role of GILZ homo-dimerization and C-terminal domain","volume":"35","author":"Di Marco","year":"2007","journal-title":"Nucleic Acids Res."},{"issue":"31","key":"10.1016\/j.jaut.2022.102858_bib24","doi-asserted-by":"crossref","first-page":"29603","DOI":"10.1074\/jbc.M101522200","article-title":"Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ","volume":"276","author":"Mittelstadt","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.jaut.2022.102858_bib25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1053\/j.gastro.2008.09.024","article-title":"Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis","volume":"136","author":"Cannarile","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2022.102858_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2015.05.010","article-title":"GILZ regulates Th17 responses and restrains IL-17-mediated skin inflammation","volume":"61","author":"Jones","year":"2015","journal-title":"J. Autoimmun."},{"issue":"8","key":"10.1016\/j.jaut.2022.102858_bib27","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s10067-017-3711-9","article-title":"Glucocorticoid-induced leucine zipper expression is associated with response to treatment and immunoregulation in systemic lupus erythematosus","volume":"36","author":"Mohammadi","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102858_bib28","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3389\/fimmu.2019.01684","article-title":"Could GILZ Be the answer to glucocorticoid toxicity in lupus?","volume":"10","author":"Flynn","year":"2019","journal-title":"Front. Immunol."},{"issue":"28","key":"10.1016\/j.jaut.2022.102858_bib29","doi-asserted-by":"crossref","first-page":"19373","DOI":"10.1074\/jbc.M113.535237","article-title":"Role of glucocorticoid-induced leucine zipper (GILZ) in bone acquisition","volume":"289","author":"Pan","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.jaut.2022.102858_bib30","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/art.37858","article-title":"Divergent effects of endogenous and exogenous glucocorticoid-induced leucine zipper in animal models of inflammation and arthritis","volume":"65","author":"Ngo","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2022.102858_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059149","article-title":"Glucocorticoid-induced leucine zipper (GILZ) regulates testicular FOXO1 activity and spermatogonial stem cell (SSC) function","volume":"8","author":"Ngo","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jaut.2022.102858_bib32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0092-8674(95)90171-X","article-title":"Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease","volume":"83","author":"Hibbs","year":"1995","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jaut.2022.102858_bib33","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4049\/jimmunol.0901878","article-title":"Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6","volume":"184","author":"Tsantikos","year":"2010","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.jaut.2022.102858_bib34","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.4049\/jimmunol.1201946","article-title":"Autophagy regulates IL-23 secretion and innate T cell responses through effects on IL-1 secretion","volume":"189","author":"Peral de Castro","year":"2012","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2022.102858_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1006\/jmbi.1994.1651","article-title":"Domains of interaction between alpha interferon and its receptor components","volume":"243","author":"Uze","year":"1994","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.jaut.2022.102858_bib36","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1038\/s41598-018-20203-9","article-title":"Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus","volume":"8","author":"Connelly","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2022.102858_bib37","series-title":"Dubois' Lupus Erythematosus and Related Syndromes","first-page":"62","article-title":"Cytokines and interferons in lupus","author":"Crow","year":"2013"},{"issue":"1","key":"10.1016\/j.jaut.2022.102858_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.molimm.2014.05.001","article-title":"Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugs","volume":"61","author":"Lyn-Cook","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jaut.2022.102858_bib39","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.3389\/fimmu.2018.03111","article-title":"Amplified host defense by toll-like receptor-mediated downregulation of the glucocorticoid-induced leucine zipper (GILZ) in macrophages","volume":"9","author":"Hoppstadter","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2022.102858_bib40","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3389\/fimmu.2018.01720","article-title":"Glucocorticoid-induced leucine zipper inhibits interferon-gamma production in B cells and suppresses colitis in mice","volume":"9","author":"Bruscoli","year":"2018","journal-title":"Front. Immunol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089684112200066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089684112200066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:29:41Z","timestamp":1760257781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089684112200066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":40,"alternative-id":["S089684112200066X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102858","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GILZ regulates type I interferon release and sequesters STAT1","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102858"}}